SSSameera Senaweera

Sameera Senaweera

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sameera Senaweera has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Haijuan Du

    Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA

    1 shared publication
  • Huanchun Zhang

    Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA

    1 shared publication
  • Jiashu Xie

    Center For Drug Design College of Pharmacy University of Minnesota Minneapolis Minnesota USA

    1 shared publication
  • Karen A. Kirby

    Center For ViroScience and Cure Laboratory of Biochemical Pharmacology Department of Pediatrics Emory University School of Medicine Children's Healthcare of Atlanta Atlanta Georgia USA

    1 shared publication
  • Philip R. Tedbury

    Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA

    1 shared publication
  • Stefanos G. Sarafianos

    Center For ViroScience and Cure Laboratory of Biochemical Pharmacology Department of Pediatrics Emory University School of Medicine Children's Healthcare of Atlanta Atlanta Georgia USA

    1 shared publication

Latest Publications

  • Open Access

    Discovery of New Small Molecule Hits as Hepatitis B Virus Capsid Assembly Modulators: Structure and Pharmacophore-Based Approaches

    by Sameera Senaweera, Haijuan Du, Huanchun Zhang, Karen A. Kirby, Philip R. Tedbury, Jiashu Xie, Stefan G. Sarafianos, Zhengqiang Wang

    Hepatitis B virus (HBV) capsid assembly modulators (CpAMs) have shown promise as potent anti-HBV agents in both preclinical and clinical studies. Herein, we report our efforts in identifying novel CpAM hits via a structure-based virtual screening against a small molecule protein-protein interaction (PPI) library, and pharmacophore-guided compound design and synthesis. Curated compounds were first assessed in a thermal shift assay (TSA), and the TSA hits were further evaluated in an antiviral assay. These efforts led to the discovery of two structurally distinct scaffolds, ZW-1841 and ZW-1847, as novel HBV CpAM hits, both inhibiting HBV in single-digit µM concentrations without cytotoxicity at 100 µM. In ADME assays, both hits displayed extraordinary plasma and microsomal stability. Molecular modeling suggests that these hits bind to the Cp dimer interfaces in a mode well aligned with known CpAMs.